ANXA2 and neoplasm: In the current study, the low ANXA2 group showed a higher rate of tumor shrinkage (CR or PR, 44.8%) compared with the high ANXA2 group (CR or PR, 18.8%), and a lower rate of therapeutic resistance (PD, 24.1%) compared with the high ANXA2 group (PD, 37.5%), although not reaching statistical significance (Fig. 1G).